{"id":498124,"date":"2020-07-23T14:24:01","date_gmt":"2020-07-23T14:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=498124"},"modified":"2020-07-23T14:24:01","modified_gmt":"2020-07-23T14:24:01","slug":"vitiligo-epidemiology-forecast-to-2030-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vitiligo-epidemiology-forecast-to-2030-leading-companies-and-competitive-analysis-by-delveinsight_498124.html","title":{"rendered":"Vitiligo Epidemiology Forecast to 2030 Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1595499376.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vitiligo Epidemiology Forecast to 2030 Leading Companies and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1595499376.png\" alt=\"Vitiligo Epidemiology Forecast to 2030 Leading Companies and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) DelveInsight has launched a new report on <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-epidemiology-forecast\" target=\"_blank\">Vitiligo Epidemiology to 2030<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s Vitiligo Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Vitiligo epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">Vitiligo as a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non\u2010scaly macules that are present with distinct margins<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/075fe57179d3acee0ac5888844b1573d.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample page<\/strong>: &#8211; <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vitiligo-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/vitiligo-epidemiology-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Vitiligo Epidemiology Perspective by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">The Vitiligo epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Vitiligo epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Vitiligo epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/p>\n<p style=\"text-align: justify;\"><strong>Vitiligo Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">Researchers have identified several forms of Vitiligo. Generalized Vitiligo (also called non\u2010segmental Vitiligo), which is the most common form, involves loss of pigment (depigmentation) in patches of skin all over the body. Another form called segmental Vitiligo (also known as unilateral or localized Vitiligo) is associated with smaller patches of depigmented skin that appear on one side of the body in a limited area; this occurs in about 10% of affected individuals. The localized type is further subdivided into focal, segmental, and mucosal subtypes, while the generalized type is subdivided into acrofacial, Vulgaris, and universal subtypes. An overlap of various types can be classified as &lsquo;mixed type.<\/p>\n<p style=\"text-align: justify;\"><strong>Key facts of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s epidemiology model suggests that overall, female population was found to be more prevalent than male population.<\/li>\n<li>The total prevalent population of Vitiligo in the seven major markets was approximately 6,234,655 in 2017.<\/li>\n<li>The United States accounted for the highest prevalent cases with around 2,663,753 prevalent cases in 2017, followed by Japan (approximately 2,141,164 cases) and EU5.<\/li>\n<li>Among the European countries, Germany has the highest prevalent population with approximately 472,057 cases followed by the UK which has prevalent population of approximately 290,965 in 2017.<\/li>\n<li>France has the lowest number of prevalent cases, among EU\u20105 countries, with around 188,196 cases in 2017.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Vitiligo report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Vitiligo Epidemiology Report and Model provide an overview of the risk factors and global trends of Vitiligo in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Vitiligo in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Vitiligo<\/li>\n<li>The report provides the segmentation of the Vitiligo epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample page<\/strong>: &#8211;&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vitiligo-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/vitiligo-epidemiology-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;Key Insights&nbsp;<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Vitiligo<\/p>\n<p style=\"text-align: justify;\">3.&nbsp;Vitiligo: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;Vitiligo Patient Journey<\/p>\n<p style=\"text-align: justify;\">5.&nbsp;Vitiligo Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">6.&nbsp;Vitiligo Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">7.&nbsp;KOL Views<\/p>\n<p style=\"text-align: justify;\">8.&nbsp;Vitiligo Unmet Needs<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;&nbsp;Appendix<\/p>\n<p style=\"text-align: justify;\">10.&nbsp;DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">11.&nbsp;Disclaimer<\/p>\n<p style=\"text-align: justify;\">12.&nbsp;About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<ul class=\"curriculum-list\" style=\"text-align: justify;\">\n<li>\n<div class=\"row\">\n<div class=\"col-lg-10 col-md-10 col-sm-10 col-xs-12 px-5\"><span style=\"text-decoration: underline;\"><strong><a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-pipeline-insight\">Vitiligo &#8211; Pipeline Insights, 2020<\/a><\/strong><\/span><\/div>\n<\/div>\n<\/li>\n<li>\n<div class=\"row\">\n<div class=\"col-lg-2 col-md-2 col-sm-2 col-xs-12\"><span style=\"text-decoration: underline;\"><strong><a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/www.delveinsight.com\/report-store\/vitiligo-market-2027\">Vitiligo &#8211; Market Insights, Epidemiology and Market Forecast-2027<\/a><\/strong><\/span><\/div>\n<\/div>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<h3 style=\"text-align: justify;\"><strong><span>&nbsp;<\/span><\/strong><\/h3>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.<\/p>\n<h3 style=\"text-align: justify;\">&nbsp;<\/h3>\n<h3 style=\"text-align: justify;\">Contact Us<\/h3>\n<p style=\"text-align: justify;\">Shruti Thakur<br \/>info@delveinsight.com<br \/>+91-9650213330<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vitiligo-epidemiology-forecast-to-2030-leading-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vitiligo-epidemiology-forecast-to-2030-leading-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, US) DelveInsight has launched a new report on Vitiligo Epidemiology to 2030 DelveInsight&#8217;s Vitiligo Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Vitiligo epidemiology in the 7MM, i.e., the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vitiligo-epidemiology-forecast-to-2030-leading-companies-and-competitive-analysis-by-delveinsight_498124.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[417,406,420,413,411],"tags":[],"class_list":["post-498124","post","type-post","status-publish","format-standard","hentry","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Science","category-Services","category-Technology"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/498124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=498124"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/498124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=498124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=498124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=498124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}